DGIdb - IDELALISIB Drug Record

IDELALISIB chembl:CHEMBL2216870 ApprovedAntineoplasticImmunotherapy

Alternate Names:

CAL-101
GS-1101
IDELALISIB
GS-11CAL-101
ZYDELIG
5-FLUORO-3-PHENYL-2-((S)-1-(9H-PURIN-6-YLAMINO)-PROPYL)-3H-QUINAZOLIN-4-ONE
5-FLUORO-3-PHENYL-2-[(1S)-1-(3H-PURIN-6-YLAMINO)PROPYL]QUINAZOLIN-4(3H)-ONE
CAL-101/CAL101
ZYDELIG®
chembl:CHEMBL2216870
chemidplus:870281-82-6
rxcui:1544460
drugbank:09054
pubchem.compound:11625818

Drug Info:

FDA Approval	Chronic lymphocytic leukemia, Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma
Drug Class	Small molecule inhibitor
Drug Class	Kinase Inhibitors
FDA Approval	not approved
Drug Class	Small molecule
Drug Indications	antineoplastic agent

(4 More Sources)

Publications:

Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol
Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.
Yahiaoui et al., 2017, PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors., PLoS ONE

IDELALISIB PIK3CD

Interaction Score: 1.32

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CAL-101

Novel drug target Novel Target

Mechanism of Interaction PI3-kinase p110-delta subunit inhibitor

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions TTD
IDELALISIB PIK3CA

Interaction Score: 0.44

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type no benefit

PMIDs:
26137449 26466009

Sources:
JAX-CKB CIViC
IDELALISIB BRAF

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type no benefit

Approval Status Preclinical

PMIDs:
26137449

Sources:
JAX-CKB
IDELALISIB PTEN

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Idelalisib + MK2206

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type predicted – sensitive

PMIDs:
28178345

Sources:
JAX-CKB

MyCancerGenome: IDELALISIB
- Version: 20-Jun-2017
Alternate Names:

ICOTINIB Generic Name

ZYDELIG Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Chronic lymphocytic leukemia, Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma

Publications:
MyCancerGenome: CAL-101
- Version: 20-Jun-2017
Alternate Names:

CAL-101 Development Name

GS-1101 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Publications:
TdgClinicalTrial: CAL-101
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

JAX-CKB: Idelalisib

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Yahiaoui et al., 2017, PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors., PLoS ONE

Sweetlove et al., 2015, Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth., Front Oncol

CIViC: IDELALISIB
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.
TTD: Idelalisib
- Version: 2020.06.01
Alternate Names:

D0J5VR TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL2216870
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL2216870
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Trial Name	CAL-101
Novel drug target	Novel Target
Mechanism of Interaction	PI3-kinase p110-delta subunit inhibitor

Evidence Type	Actionable
Approval Status	Preclinical
Response Type	no benefit

Indication/Tumor Type	melanoma
Response Type	no benefit
Approval Status	Preclinical

combination therapy	Idelalisib + MK2206
Indication/Tumor Type	diffuse large B-cell lymphoma
Response Type	predicted – sensitive

ICOTINIB	Generic Name
ZYDELIG	Trade Name

IDELALISIB Drug Record

IDELALISIB chembl:CHEMBL2216870 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

IDELALISIB PIK3CD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name CAL-101 Novel drug target Novel Target Mechanism of Interaction PI3-kinase p110-delta subunit inhibitor

PMIDs: None found

Sources: MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

IDELALISIB PIK3CA

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type no benefit

PMIDs: 26137449 26466009

Sources: JAX-CKB CIViC

IDELALISIB BRAF

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type melanoma Response Type no benefit Approval Status Preclinical

PMIDs: 26137449

Sources: JAX-CKB

IDELALISIB PTEN

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Idelalisib + MK2206 Indication/Tumor Type diffuse large B-cell lymphoma Response Type predicted – sensitive

PMIDs: 28178345

Sources: JAX-CKB

MyCancerGenome: IDELALISIB

Alternate Names: ICOTINIB Generic Name ZYDELIG Trade Name

Drug Info: Drug Class Small molecule inhibitor FDA Approval Chronic lymphocytic leukemia, Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma

Publications:

MyCancerGenome: CAL-101

Alternate Names: CAL-101 Development Name GS-1101 Development Name

Drug Info: Drug Class Kinase Inhibitors

Publications:

TdgClinicalTrial: CAL-101

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class Small molecule FDA Approval not approved

Publications:

JAX-CKB: Idelalisib

Alternate Names:

Drug Info:

CIViC: IDELALISIB

Alternate Names:

Drug Info:

Publications: Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.

TTD: Idelalisib

Alternate Names: D0J5VR TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL2216870

Alternate Names:

Drug Info:

Publications:

ChemblInteractions: CHEMBL2216870

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CAL-101

Novel drug target Novel Target

Mechanism of Interaction PI3-kinase p110-delta subunit inhibitor

PMIDs:
None found

Sources:
MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type no benefit

PMIDs:
26137449 26466009

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type melanoma

Response Type no benefit

Approval Status Preclinical

PMIDs:
26137449

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Idelalisib + MK2206

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type predicted – sensitive

PMIDs:
28178345

Sources:
JAX-CKB

Alternate Names:

ICOTINIB Generic Name

ZYDELIG Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Chronic lymphocytic leukemia, Follicular B-cell non-Hodgkin lymphoma, Small lymphocytic lymphoma

Alternate Names:

CAL-101 Development Name

GS-1101 Development Name

Drug Info:

Drug Class Kinase Inhibitors

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small molecule

FDA Approval not approved

Publications:

Shiver et al., 2015, Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma., N. Engl. J. Med.

Alternate Names:

D0J5VR TTD Drug ID